Roth Capital initiated coverage on shares of Panbela Therapeutics (NASDAQ:PBLA – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a buy rating and a $10.00 target price on the stock.
Separately, Maxim Group cut shares of Panbela Therapeutics from a buy rating to a hold rating in a research report on Wednesday, October 12th.
Panbela Therapeutics Stock Performance
Panbela Therapeutics stock opened at $1.51 on Tuesday. Panbela Therapeutics has a 1 year low of $1.41 and a 1 year high of $96.00. The firm has a 50 day moving average price of $0.83 and a 200 day moving average price of $0.65. The company has a market cap of $1.19 million, a price-to-earnings ratio of -0.02 and a beta of 2.22.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. acquired a new position in shares of Panbela Therapeutics during the third quarter worth $60,000. Armistice Capital LLC acquired a new position in shares of Panbela Therapeutics during the third quarter worth $588,000. UBS Group AG lifted its position in shares of Panbela Therapeutics by 46,589.5% during the third quarter. UBS Group AG now owns 190,493 shares of the company’s stock worth $51,000 after purchasing an additional 190,085 shares in the last quarter. Finally, Clear Street LLC acquired a new position in shares of Panbela Therapeutics during the third quarter worth $30,000. 9.37% of the stock is owned by institutional investors and hedge funds.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types.
- Get a free copy of the StockNews.com research report on Panbela Therapeutics (PBLA)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.